ERBB2 and non-small cell lung carcinoma: Also, in the Phase II clinical trial DESTINY‐Lung02 [50], T‐DXd in metastatic NSCLC with HER2 mutations showed an ORR of 53.8% and a median DoR of 8.7 months.